TNFRSF6B and prostate carcinoma: We additionally identified proteins with evidence for a directionally concordant and colocalised association with some, but not all, prostate cancer outcomes, including TNFRSF6B, which had an inverse association with all outcomes but only showed evidence in favour of colocalisation for aggressive disease [OROverall = 0.53, 95% CI: 0.46–0.61, PP4: 0.00; ORAggressive = 0.48, 95% CI: 0.0.37–0.63, PP4: 0.90; OREarly Onset = 0.43, 95% CI: 0.29–0.63, PP4: 0.14, Fig. 2, Supplementary Table S3].